The high diagnostic performance of PET/CT imaging using radiolabeled prostate-specific membrane antigen (PSMA) in the assessment of prostate cancer has been shown in a large number of recent published data, particularly in the recurrent setting of the disease. The gene discussed is FOLH1; the disease is Familial prostate cancer.